TAGE Score for Symptomatic Intracranial Hemorrhage Prediction After Successful Endovascular Treatment in Acute Ischemic Stroke

Well fuck, you solve the problem of preventing intracranial hemorrhage rather than this lazy prediction research. I'd have you all fired for totally missing the objectives of all stroke research; 100% recovery.

Didn't this research from March 2021 already answer this question? And your mentors and senior researchers didn't know about it and approved this anyway. My god, there is a lot of dead wood in stroke that needs to be removed.

Early Venous Filling Following Thrombectomy: Association With Hemorrhagic Transformation and Functional Outcome March 2021

The latest here:

TAGE Score for Symptomatic Intracranial Hemorrhage Prediction After Successful Endovascular Treatment in Acute Ischemic Stroke

Paul Janvier

,

Basile Kerleroux

,

Guillaume Turc

,

Marco Pasi

,

Wassim Farhat

,

Nicolas Bricout

,

Joseph Benzakoun

,

Laurence Legrand

,

Frédéric Clarençon

,

Serge Bracard

, … See all authors

Originally published14 Jun 2022https://doi.org/10.1161/STROKEAHA.121.038088Stroke. 2022;0:10.1161/STROKEAHA.121.038088

Abstract

Background:

Determine if early venous filling (EVF) after complete successful recanalization with mechanical thrombectomy in acute ischemic stroke is an independent predictor of symptomatic intracranial hemorrhage (sICH) and integrate EVF into a risk score for sICH prediction.

Methods:

Consecutive patients with anterior acute ischemic stroke treated by mechanical thrombectomy issued from patients enrolled in the THRACE trial (Thrombectomie des Artères Cérébrales) and from 2 prospective registries were included and divided into a derivation (Center I; n=402) and validation cohorts (THRACE and center 2; n=507). EVF was evaluated by 2 blinded readers. sICH was defined according to the modified European cooperative acute stroke study II. Clinical and radiological data were analyzed in the derivation cohort (C1) to identify independent predictors of sICH and construct a predictive score test on the validation cohort (THRACE + C2).

Results:

Symptomatic ICH rate was similar between the two cohorts (9.9% and 8.9% respectively, P=0.9). Time from onset-to-successful recanalization >270 minutes (odds ratio [OR], 7.8 [95% CI, 2.5–24]), Alberta Stroke Program Early CT Score (≤5 [OR, 2.49 (95% CI, 1.8–8.1) or 6–7 [OR, 1.15 (95% CI, 1.03–4.46)]), glucose blood level >7 mmol/L (OR, 2.92 [95% CI, 1.26–6.7]), and EVF presence (OR, 11.9 [95% CI, 3.8–37.5]) were independent predictors of sICH and constituted the Time–Alberta Stroke Program Early CT–Glycemia–EVF score. Time–Alberta Stroke Program Early CT–Glycemia–EVF score was associated with an increased risk of sICH in the derivation cohort (OR increase per unit, 1.99 [95% CI, 1.53–2.59]; P<0.001) with area under the curve, 0.832 [95% CI, 0.767–0.898]. The score had good performance in the validation cohort (area under the curve, 0.801 [95% CI, 0.69–0.91]).

Conclusions:

Time–Alberta Stroke Program Early CT–Glycemia–EVF score is a simple tool with readily available clinical variables with good performances for sICH prediction after mechanical thrombectomy.

REGISTRATION:

URL: https://www.clinicaltrials.gov; Unique identifier: NCT01062698.

• Download figure
• Download PowerPoint